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Abstract
Studies over the last 20 years have demonstrated that increased inﬂammation and hyperactivity of
the hypothalamic–pituitary–adrenal (HPA) axis are two of the most consistent biological ﬁndings in
major depression and are often associated: but the molecular and clinical mechanisms underlying
these abnormalities are still unclear. These ﬁndings are particularly enigmatic, especially considering
the accepted notion that high levels of cortisol have an anti-inﬂammatory action, and therefore the
coexistence of inﬂammation and hypercortisolemia in the same diagnostic group appears counter-
intuitive. To celebrate the 2015 Anna-Monika Foundation Award to our laboratory, this review will
discuss our own 20 years of research on the clinical and molecular evidence underlying the increased
inﬂammation in depression, especially in the context of a hyperactive HPA axis, and discuss its
implications for the pathogenesis and treatment of this disorder.
& 2017 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Winning the prestigious Anna-Monika Foundation Award has
been an ideal opportunity for me to reﬂect on the research that
has been coming out of our laboratory over the last 20 years,
especially since this long period of time has seen a very
important theoretical advance in psychiatry: the transformation
of psychoneuroimmunology (or, as it has been more recently
called, immunopsychiatry) from a niche area of biological
psychiatry and psychosomatics to an established mainstream
research and translational area in mental health and clinical
neuroscience (Pariante, 2015). Because of the focus of this
review on our scientiﬁc production within the larger immunop-
sychiatry framework, the narrative and the citations are self-
referential. However, this scientiﬁc production would not exist
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if we had not been supported by a number of friends,
colleagues and collaborators who have shaped psychoneuroim-
munology over the years.
2. Inﬂammation and the glucocorticoid
receptor: love at ﬁrst sight
Although my ﬁrst publication on depression and immune
system dates back to 1991 (Bartoloni et al., 1991), what
really deﬁned my future as researcher in this ﬁeld was my
encounter with the glucocorticoid receptor (GR) in the
laboratory of Andrew H Miller at Emory University in
Atlanta, in the years 1995–1997. At that time, it was well
known that a hyperactivity of the hypothalamic–pituitary–
adrenal (HPA) axis can be consistently identiﬁed in at least a
subgroup of depressed patients. The prevailing model at
that time – which is pretty much still unchanged today – was
based on the notion of “glucocorticoid resistance”. In a
nutshell, the glucocorticoid receptor (one of the two
receptors for the human glucocorticoid hormone, cortisol)
physiologically mediates the HPA axis negative feedback,
that is, the ability of cortisol to inhibit its own secretion,
especially during an increased production due to stress; in
contrast, in depression, a dysfunction of the GR leads to an
impaired HPA axis negative feedback (a phenomenon called
glucocorticoid resistance), which in turn leads to the HPA
axis hyperactivity (Pariante and Lightman, 2008; Pariante
and Miller, 2001). While this theoretical model was already
established at that time, very little was known on the
molecular mechanisms that could underpin these presumed
GR abnormalities. To address this question, we started using
a scientiﬁc approach that has continued to deliver many
interesting ﬁndings over the years: we exploited in vitro
models utilising ﬁbroblasts, human blood cells, and neurons.
In the ﬁrst paper on this topic, we found that incubating L929
mouse ﬁbroblasts cells with the pro-inﬂammatory cytokine
interleukin (IL)-1 leads to glucocorticoid resistance, i.e., to an
impairment of GR activation and translocation from the
cytoplasm to the nucleus, resulting in reduced expression of
GR-stimulated genes (Pariante et al., 1999). Interestingly, at
the same time we also demonstrated that antidepressants
in vitro increase GR activation and function, that is, reverse
glucocorticoid resistance, thus conﬁrming the crucial role of the
GR as a target of both depressogenic (inﬂammation) and
therapeutic (antidepressants) stimuli (Pariante et al., 1997).
Two subsequent papers demonstrated similar ﬁndings in human
peripheral blood mononuclear cells (Carvalho et al., 2008,
2010).
An interesting side-story following these initial ﬁndings
was a series of subsequent studies (conducted in London) in
which we demonstrated that the effects of antidepressants
potentiating GR translocation and function is not only
directly mediated through steroid-independent activation
of the GR, but also indirectly by inhibition of the p-
glycoprotein transporter that expels cortisol from cells
(and, in vivo, from the brain). We found that, in vitro,
these effects are common to all tested antidepressants and
are present not only in mouse ﬁbroblasts but also in rat
neurons (Pariante et al., 2001, 2003a. 2003b, 2004b). In
subsequent animal studies, we were able to demonstrate
that p-glycoprotein regulates the effects of antidepressants
on GR expression (Yau et al., 2007) but not, however, that p-
glycoprotein or indeed antidepressants regulate cortisol
levels in the brain (Mason et al., 2008, 2011).
3. From cells to humans
After moved to London in 1997, I expanded my research
portfolio to include clinical studies. In 2008 we described
increased plasma cortisol levels and increased inﬂammation
(plasma IL-6) in the same depressed individuals, a group of
severely depressed inpatients with treatment-resistant depres-
sion (Carvalho et al., 2008); moreover, these same subjects
have glucocorticoid resistance, as shown by a reduced in vitro
ability of their peripheral blood mononuclear cells to respond to
dexamethasone and cortisol during an immune stimulus
(Carvalho et al., 2009). Patients with the highest IL-6 levels
are also the least likely to respond to antidepressants (Carvalho
et al., 2013). These ﬁndings conﬁrmed the notion that gluco-
corticoid resistance, cortisol hypersecretion and increased
inﬂammation are indeed coexistent and related biological
abnormalities. In two studies in healthy volunteers, we were
also able to conﬁrm that antidepressants reverse GR resistance,
that is, increase GR function as measured by the HPA axis
negative feedback (Pariante et al., 2004a) and the effects of
cortisol on the EEG (Pariante et al., 2012). But these studies,
while conﬁrming that these biological changes are operating in
man, did not help elucidate the potential molecular mechan-
isms underlying GR resistance in depression, nor its reversal by
antidepressants.
To try to understand such molecular mechanisms, we
measured the expression of candidate genes in the peripheral
blood mRNA of patients with major depression (and healthy
controls) from the GENDEP sample, a large European study
funded by the European Commission. In this study, we found
two noticeable results: ﬁrst, we replicated the increased
inﬂammation in depression as shown by increased mRNA
expression of proinﬂammatory cytokines (IL-1, IL-6, TNF-alpha
and macrophage inhibiting factor, MIF) together with a reduced
expression of the anti-inﬂammatory cytokines, IL-4; and,
second, we showed that these same patients also have
molecular evidence of GR resistance as shown by a reduced
expression of GR mRNA together with an increased expression
of the GR chaperone protein, FKBP5 (Cattaneo et al., 2013).
Both these ﬁndings indicate the possible molecular signature
underlying GR resistance and increased inﬂammation in depres-
sion: a reduced GR expression (that is, less receptor available)
together with a decreased GR responsivity (as FKBP5 binds to
the GR and maintains it in an unresponsive state).
We subsequently tested the same hypotheses in an
independent study, in which we measured HPA axis activity
and inﬂammation in a group of older depressed patients
with coronary heart disease. We were particularly inter-
ested in this group, as coronary heart disease is charac-
terised by higher levels of chronic inﬂammation, and hence
we hypothesised that depression in this context would have
shown clear abnormalities of the immune system. And,
indeed, this is exactly what we found: depressed patients
with coronary heart disease have higher inﬂammation
(higher IL-6 mRNA and higher levels of c-reactive protein
(CRP), an acute phase response protein produced by the
liver in response to IL-6) together with a reduced expression
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of GR mRNA; that is, the same results that we had found in
the GENDEP sample (Nikkheslat et al., 2015). Interestingly
however, these ﬁndings were not associated with HPA axis
hyperactivity but rather with hypoactivity. This biological
picture, perhaps due to the advanced age of the subjects in
questions and thus to the long chronicity of their depres-
sion, introduces a different type of GR resistance: an
ineffective GR together with lower levels of cortisol
(Nikkheslat et al., 2015).
4. And from humans to cells
While pursuing these clinical studies, we continued to use
in vitro models in order to dissect the molecular mechanisms
underlying these GR- and inﬂammation-related abnormalities,
and their reversal by antidepressants. In particular, in the last
few years we have used models of ‘depression in a dish’ where
human neurones or neuronal hippocampal progenitor cells (able
to differentiate into neurons) are treated with depressogenic
stimuli (such as cortisol and IL-1), or with antidepressants and
antidepressants-like compounds (such as anti-inﬂammatories
and omega-3 fatty acids). Using these in vitro models, we have
extended our research questions to include the understanding
of whether inﬂammation exert a depressogenic effects by
decreasing neurogenesis or by increasing neurotoxicity, and of
whether the GR is involved in the rescue effects of antide-
pressants on neurogenesis.
With regard to the ﬁrst question, we found that two pro-
inﬂammatory cytokines, IL-1 and interferon-alpha, reduce
human neurogenesis and human neuronal survival, an effect
that is mediated by an increased production of neurotoxic
tryptophan metabolites as well as an increased oxidative stress
(Alboni et al., 2013; Horowitz et al., 2014; Zunszain et al.,
2012). We also showed that the detrimental effects of these
inﬂammatory stimuli can be reversed by antidepressant treat-
ments as diverse as inhibitors of the kynurenine pathways,
antioxidants and mitochondrial modulators, and omega-3 poly-
unsaturated fatty acids (Alboni et al., 2013; Horowitz et al.,
2014; Zunszain et al., 2012).
With regard to the second question, we indeed demonstrated
that antidepressants not only increase neurogenesis, but do so
by activating a downstream cascade of second messenger
mechanisms that requires the GR (Anacker et al., 2011). In
fact, our most interesting ﬁnding in this ﬁeld was the evidence
that both antidepressants and cortisol require the GR to exert
their effects on neurogenesis: but with antidepressants activat-
ing the GR in order to increase neurogenesis, while cortisol
activating the GR in order to decrease neurogenesis. This
apparent contradiction is due to the fact that different
activators of the GR induce different patterns of GR phosphor-
ylation and activation, eventually leading to different sets of
downstream GR-stimulated genes. Speciﬁcally, antidepressants
increase neurogenesis via a GR-dependent mechanism that
requires protein kinase A (PKA) signalling and upregulation of
genes such as p11 and the cyclin-dependent kinase-2 (CDK2)
inhibitors, p27and p57 (Anacker et al., 2011), while cortisol
decreases neurogenesis via activation and upregulation of the
GR-stimulated gene, serum- and glucocorticoid-inducible kinase
1 (SGK1), leading to inhibition of TGFβ- SMAD2/3- and Hedge-
hog signalling (Anacker et al., 2013a, 2013b). Of note, although
all of these results were initially from in vitro experiments, we
were able to replicate both the antidepressant-induced upre-
gulation of p11 and the cortisol-induced upregulation of SGK1 in
the blood (mRNA) of depressed patients, and the cortisol-
induced downregulation of TGFβ-SMAD2/3 and Hedgehog sig-
nalling in the hippocampus of adult rats exposed to prenatal
stress (Anacker et al., 2013a, 2013b).
5. Why are some depressed patients
inﬂamed?
Not all depressed patients have increased inﬂammation: so,
who are these patients that present with this biological
phenotype? What is their corresponding clinical phenotype? In
2007, working with Avshalom Caspi and Terrie Mofﬁtt on the
Dunedin study, we were the ﬁrst to demonstrate that young
adults with a history of childhood trauma show increased
inﬂammation, as demonstrated by increased CRP, increased
white blood cell counts and increased ﬁbrinogen levels (Danese
et al., 2007). In subsequent reports, we showed that this
increased inﬂammation is present not only in subjects who are
depressed and have a history of childhood maltreatment but
also in those who have experienced maltreatment but are not
depressed (Danese et al., 2008); moreover, the increased
inﬂammation clusters with metabolic risk biomarkers such as
being overweight or presenting with high blood pressure, high
total cholesterol and high glycated hemoglobin (Danese et al.,
2009). Together, these ﬁndings indicate that the increased
inﬂammation is a ‘biological scar’ of the early exposure to high
levels of stress, which originates in childhood and is charac-
terised by abnormalities in both mental and physical health
(Baumeister et al., 2016).
More recently, we have been able to replicate the association
between early life trauma and increased inﬂammation also in
12-year-old children (Danese et al., 2011), and, most interest-
ingly, in young adults who have been exposed to stress not in
childhood but even earlier: in utero (Plant et al., 2016). For this
latter study, we have followed-up the offspring of the South
London Child Development Cohort, a longitudinal sample of
depressed women who were recruited and assessed during
pregnancy in 1986 (together with control pregnant women),
and subsequently assessed with their offspring during childhood
and adolescence. Over the years, this cohort has demonstrated
that exposure to maternal depression during pregnancy (but not
in the postpartum period) doubles the risk of the offspring
developing themselves depression and other mental disorders in
adolescence (Pawlby et al., 2011), and association that is
mediated, at least in part, by an increased risk of the offspring
being exposed to maltreatment and other stressful events in
childhood (Plant et al., 2013, 2015). We have recently pub-
lished that these same offspring exposed to maternal depres-
sion in utero, now young adults, have increased inﬂammation
as shown by raised CRP levels (Plant et al., 2016). Moreover, we
have ﬁnd some preliminary evidence that exposure to
medically-related inﬂammation in childhood (for example
through infections and autoimmune disorders) also increase
the risk of depression in adulthood (Du Preez et al., 2016).
Taken together, all these lines of evidence indicate that
increased inﬂammation is present in a subgroup of depressed
patients who have a neurodevelopmentally-based form of
depression, originating from exposure to stress (or possibly
directly to inﬂammation) early in childhood or even in utero.
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However, the neurodevelopmental origin may not be the only
path to increased inﬂammation in depression. There is consis-
tent evidence from candidate gene studies that genetic variants
that increase immune responses are more frequent in patients
with depression, or characterise a group of individuals who are
at risk of developing a depressive phenotype in the context of
an immune challenge (Barnes et al., 2017). For example, a few
years ago we published that the functional G-174C polymorph-
ism (rs1800795) in the promoter region of the IL-6 gene predicts
depressive symptoms in patients taking interferon-alpha for
chronic viral hepatitis (Bull et al., 2009). In a different study in
a similar population, we have also found that two polymorph-
isms in genes regulating prostaglandin synthesis, the BanI
polymorphism of the cytosolic phospholipase A2 (cPLA2) and
the COX2 rs4648308 polymorphism in the cyclooxygenase 2
(COX-2) genes, also regulate the risk of developing interferon-
alpha induced depression (Su et al., 2010). Interestingly, this
latter study also offered us an opportunity for investigating the
molecular mechanisms underlying this genetic predisposition:
indeed, carriers of the two ‘at risk’ PLA2 and COX2 genotypes
also have lower levels of the omega-3 fatty acids, docosahex-
aenoic acid (DHA) and eicosapentaenoic acid (EPA), before and
during IFN-α treatment (Su et al., 2010). Considering the
putative antidepressants and anti-inﬂammatory action of these
omega-3 fatty acids, we speculated that genetically-driven low
levels of these endogenous anti-inﬂammatory compounds
increase the risk of interferon-alpha induced depression.
Indeed, in a subsequent clinical trial we have recently demon-
strated that prophylactic treatment with EPA and DHA prevents
or delays the onset of interferon-alpha-induced depression (Su
et al., 2014). This latter study truly shows the full translational
potential of this area of research.
6. Are these ﬁndings clinically relevant?
Perhaps our most clinically-relevant contribution to the ﬁeld
of depression and inﬂammation comes from our studies using
immune biomarkers to predict response to antidepressants. In
the ﬁrst such study based on the GENDEP sample, mentioned
above (Cattaneo et al., 2013), we measured mRNA expression
of genes belonging to inﬂammation, before and after eight
weeks of treatment with antidepressants. We found that
depressed patients who do not go on to respond to the
prescribed antidepressants (escitalopram or desipramine) have
higher baseline mRNA levels of IL-1, MIF and TNF-alpha.
Together, the levels of these three cytokines predict approxi-
mately half of the variance in antidepressant response,
although IL-1 and MIF explain most of the variance. We then
replicated these ﬁndings in a second independent cohort of
depressed patients, and using a novel “absolute mRNA values”
measurement approach that allows easier comparability in-
between laboratories. In this second cohort, we have con-
ﬁrmed and extended the predictive ability of IL-1 and MIF, and
have identiﬁed cut-off values for the absolute mRNA measures
that accurately predict response probability at an individual
level, with positive predictive values and speciﬁcity for non-
responders of 100% (Cattaneo et al., 2016). These latter
ﬁndings were reported by a number of news outlets, leading
to a Altimetric score of 1040 (top 1% for impact).
These series of studies not only have provided consistent
evidence that increased inﬂammation characterizes a
subgroup of depressed patients that is less likely to respond
to conventional antidepressants, but also have established
the measurement of blood mRNA immune genes as a reliable
and clinically signiﬁcant biomarker in the context of psy-
choneuroimmunology, to complement (and at times surpass)
the routine measurement of serum/plasma cytokines
(Hepgul et al., 2013). Indeed, in a recent paper we have
examined the mRNA transcriptomics proﬁle of patients
taking interferon-alpha, and shown that patients who
develop depression during this immune challenge present
a hyperactive immune response that is evident by measuring
mRNA but not plasma cytokines (Hepgul et al., 2016).
Finally, although this review focuses on our work in
depression, it is important also to mention our contribution
to the increasing evidence that an activated inﬂammatory
system is also relevant for patients with psychotic disorders,
such as schizophrenia, by affecting physical health, brain
structure, clinical outcome and the action of antipsychotics
(Di Nicola et al., 2013; Handley et al., 2016; Hepgul et al.,
2012; Mondelli et al., 2011, 2015; Russell et al., 2015).
7. Conclusions
A rapid 20-year helicopter view on our scientiﬁc production
has allowed us to identify successful answers but also out-
standing questions in this research area. The ﬁeld has
burgeoned in the last few years, and we have now clear
translational opportunities for psychoneuroimmunology and
immunopsychiatry to help patients, delivering both predictive
biomarkers to implement precision psychiatry and novel
pharmacological agents that improves depression through an
anti-inﬂammatory action. But questions still exist. What are
the epigenetic mechanisms by which early life events – as
early as in utero – create a long-term trajectory of increased
inﬂammation? How do anti-inﬂammatories help depression,
and are there differences between different anti-
inﬂammatories in their antidepressant effects? How can we
successfully reverse glucocorticoid resistance, and is normal-
ising GR function helpful for depressed patients? Some of
these answers maybe behind the corner, some may take 20
more years – but one thing is for sure: depression, and mental
health problems in general, can no longer be seen only as
disorders of the mind, or indeed only as disorders of the
brain. The strong impact of the immune system on emotions
and behaviour demonstrates that mental health is the health
of the whole body.
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